Clinical Trails

Interim results from the phase 2 ALPHA3 trial suggest that cema-cel, an off-the-shelf CAR T-cell therapy, may significantly improve outcomes for patients with large B-cell lymphoma who remain MRD-positive after initial treatment. In this high-risk group, the therapy achieved MRD negativity in 58.3% of patients, compared to just 16.7% with standard observation. Circulating tumor DNA […]

A phase 1 trial shows that a dual-target CAR T-cell therapy called AZD0120 is highly effective and safe for older adults with newly diagnosed multiple myeloma, including frail patients. The study included patients with a median age of 72 and found extremely strong early results. All patients achieved a complete response and no detectable cancer

CellCentric has treated the first patient in the DOMMINO-1 trial, a Phase 2 study testing an all-oral combination of inobrodib, pomalidomide, and dexamethasone (InoPd) for patients with heavily pretreated, relapsed or refractory multiple myeloma. The trial plans to enroll 100 patients in the US and UK, focusing on those who are “triple-class refractory” and often

Results from a Phase 1 study show that Erda-iDRS (TAR-210), a new drug-delivery system placed directly into the bladder, appears to be both safe and effective for patients with FGFR-altered non–muscle-invasive bladder cancer. In high-risk patients, the treatment kept cancer from coming back for a median of 20 months, with 83% of patients remaining recurrence-free

A new early-phase clinical trial suggests that Enolen, a novel implant designed to deliver the prostate cancer drug enzalutamide directly into tumors, is both safe and practical for patients with early-stage disease. Researchers reported that no serious side effects above grade 3 were linked to either the implant procedure or the drug itself. Most patients

A phase 2 study shows that combining venetoclax and ibrutinib can produce strong and lasting responses in patients with marginal zone lymphoma, including those newly diagnosed and those whose disease has returned or resisted treatment. In the study of 14 patients, 79% responded to the treatment within 16 weeks, and 29% achieved a complete response.

A Phase 1 trial shows that trastuzumab rezetecan (SHR-A1811), a next-generation antibody-drug conjugate (ADC), is effective and well-tolerated in patients with HER2-expressing gastric (GC/GEJ) and colorectal cancers (CRC). Trastuzumab rezetecan works like a “smart bomb”: the HER2-targeting antibody directs the drug to cancer cells, while a linked chemotherapy payload is released inside tumors, limiting damage

A Phase 1 clinical trial suggests that adding the targeted drug VIC-1911 to standard care after donor stem cell transplants may greatly improve outcomes for patients with blood cancers. After a transplant, doctors must balance preventing graft-versus-host disease (GVHD), where donor immune cells attack the patient, while preserving the graft-versus-tumor effect that helps destroy cancer.

The Phase 3 SENTRY trial shows that adding selinexor (Xpovio) to ruxolitinib (Jakafi) improves outcomes for patients newly treated for myelofibrosis, especially in reducing spleen size. At 24 weeks, 50% of patients receiving the combination therapy achieved at least a 35% reduction in spleen volume, compared with 28% of those taking ruxolitinib alone. However, the

Researchers have developed a more advanced version of an oncolytic vaccinia virus, designed to safely target and kill cancer cells while sparing healthy tissue. Although this type of “living drug” has shown promise, earlier versions faced key challenges, including safety concerns from uncontrolled viral spread, risk of infecting others through skin lesions, and difficulty tracking